Zengsheng Pharmaceutical: Subsidiary innovative drug RAY1225 injection received ethical approval for two hypoglycemia Phase III clinical trials.

On the evening of May 25th, Zhongsheng Pharmaceutical announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., independently developed an innovative peptide drug, RAY1225 injection, for type 2 diabetes patients. Two Phase III clinical trials have obtained approval to carry out the project by the ethics review committee of the lead unit, Peking University People's Hospital. RAY1225 injection is an innovative structured peptide drug with global independent intellectual property rights, possessing dual agonistic activity on GLP-1 receptor and GIP receptor.